 Jennifer Taylor-Cousar
Concepts (296)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 96 | 2024 | 955 | 19.940 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 60 | 2024 | 287 | 12.720 |
Why?
| | Quinolones | 22 | 2024 | 97 | 8.420 |
Why?
| | Aminophenols | 34 | 2024 | 112 | 7.820 |
Why?
| | Benzodioxoles | 22 | 2024 | 83 | 5.180 |
Why?
| | Chloride Channel Agonists | 20 | 2023 | 62 | 4.230 |
Why?
| | Sinusitis | 9 | 2023 | 174 | 3.630 |
Why?
| | Indoles | 13 | 2024 | 300 | 2.750 |
Why?
| | Rhinitis | 7 | 2023 | 128 | 2.640 |
Why?
| | Aminopyridines | 5 | 2018 | 81 | 2.140 |
Why?
| | Mutation | 33 | 2023 | 3338 | 2.040 |
Why?
| | Olfaction Disorders | 5 | 2023 | 50 | 1.950 |
Why?
| | Membrane Transport Modulators | 3 | 2020 | 6 | 1.940 |
Why?
| | Drug Combinations | 18 | 2023 | 286 | 1.730 |
Why?
| | Pyrazoles | 12 | 2024 | 361 | 1.640 |
Why?
| | Azithromycin | 7 | 2021 | 80 | 1.370 |
Why?
| | Reproductive Health | 8 | 2023 | 70 | 1.280 |
Why?
| | Pyrrolidines | 8 | 2024 | 55 | 1.270 |
Why?
| | Pyridines | 9 | 2024 | 419 | 1.180 |
Why?
| | Pregnancy Complications | 4 | 2021 | 430 | 1.170 |
Why?
| | Humans | 103 | 2024 | 114045 | 1.170 |
Why?
| | Respiratory System Agents | 2 | 2020 | 22 | 1.170 |
Why?
| | Adult | 48 | 2023 | 30375 | 0.990 |
Why?
| | Paranasal Sinuses | 4 | 2023 | 66 | 0.980 |
Why?
| | Pongo pygmaeus | 2 | 2021 | 6 | 0.970 |
Why?
| | Pregnancy | 15 | 2023 | 5499 | 0.940 |
Why?
| | Reproductive Techniques, Assisted | 2 | 2023 | 32 | 0.920 |
Why?
| | Pregnancy Rate | 3 | 2021 | 54 | 0.910 |
Why?
| | Pongo | 2 | 2021 | 6 | 0.880 |
Why?
| | Anti-Bacterial Agents | 11 | 2022 | 1471 | 0.870 |
Why?
| | Female | 55 | 2023 | 59324 | 0.830 |
Why?
| | Diabetes Mellitus | 2 | 2022 | 898 | 0.780 |
Why?
| | Pseudomonas Infections | 8 | 2022 | 184 | 0.760 |
Why?
| | Sexual Health | 4 | 2023 | 46 | 0.750 |
Why?
| | Parents | 4 | 2023 | 1181 | 0.720 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 19 | 0.720 |
Why?
| | Ape Diseases | 2 | 2021 | 6 | 0.710 |
Why?
| | Lung | 9 | 2023 | 3521 | 0.700 |
Why?
| | Drug Approval | 2 | 2023 | 78 | 0.700 |
Why?
| | Quality of Life | 13 | 2023 | 2343 | 0.700 |
Why?
| | Compassionate Use Trials | 1 | 2019 | 7 | 0.680 |
Why?
| | Drug Monitoring | 6 | 2020 | 184 | 0.670 |
Why?
| | Aerosols | 1 | 2020 | 150 | 0.670 |
Why?
| | Precision Medicine | 2 | 2021 | 335 | 0.670 |
Why?
| | Pseudomonas aeruginosa | 9 | 2022 | 298 | 0.650 |
Why?
| | Sputum | 5 | 2022 | 286 | 0.650 |
Why?
| | Pregnancy Outcome | 5 | 2021 | 337 | 0.610 |
Why?
| | Chronic Disease | 9 | 2023 | 1577 | 0.600 |
Why?
| | Treatment Outcome | 15 | 2023 | 9049 | 0.600 |
Why?
| | Prospective Studies | 11 | 2023 | 6195 | 0.600 |
Why?
| | Forced Expiratory Volume | 11 | 2023 | 471 | 0.590 |
Why?
| | Breast Feeding | 2 | 2022 | 366 | 0.580 |
Why?
| | Male | 42 | 2023 | 55396 | 0.580 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 239 | 0.560 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2017 | 29 | 0.550 |
Why?
| | Rifampin | 1 | 2017 | 68 | 0.540 |
Why?
| | Pongo abelii | 1 | 2016 | 2 | 0.530 |
Why?
| | Glucose Tolerance Test | 1 | 2016 | 343 | 0.500 |
Why?
| | Child | 18 | 2023 | 18401 | 0.490 |
Why?
| | Glucose Intolerance | 1 | 2016 | 137 | 0.490 |
Why?
| | Sildenafil Citrate | 2 | 2014 | 57 | 0.490 |
Why?
| | Biomedical Research | 1 | 2020 | 582 | 0.480 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2020 | 453 | 0.480 |
Why?
| | Bronchiectasis | 1 | 2016 | 106 | 0.470 |
Why?
| | Tobramycin | 5 | 2019 | 47 | 0.470 |
Why?
| | Leukocyte Elastase | 1 | 2014 | 71 | 0.470 |
Why?
| | Genetic Therapy | 3 | 2023 | 256 | 0.440 |
Why?
| | Surveys and Questionnaires | 7 | 2023 | 4595 | 0.420 |
Why?
| | Lactation | 3 | 2022 | 149 | 0.400 |
Why?
| | Sweat | 7 | 2021 | 38 | 0.390 |
Why?
| | Smell | 2 | 2023 | 111 | 0.390 |
Why?
| | Double-Blind Method | 9 | 2023 | 1656 | 0.370 |
Why?
| | Adolescent | 19 | 2023 | 17800 | 0.370 |
Why?
| | Homozygote | 4 | 2021 | 187 | 0.360 |
Why?
| | Respiratory Function Tests | 5 | 2021 | 522 | 0.360 |
Why?
| | Quinolines | 2 | 2021 | 129 | 0.350 |
Why?
| | Young Adult | 16 | 2023 | 10444 | 0.340 |
Why?
| | Drug Interactions | 4 | 2020 | 337 | 0.340 |
Why?
| | International Cooperation | 2 | 2020 | 169 | 0.330 |
Why?
| | Hypoventilation | 1 | 2009 | 7 | 0.330 |
Why?
| | Genotype | 7 | 2023 | 1757 | 0.320 |
Why?
| | Respiratory Muscles | 1 | 2009 | 28 | 0.320 |
Why?
| | Parenting | 2 | 2023 | 252 | 0.320 |
Why?
| | ABO Blood-Group System | 1 | 2009 | 29 | 0.320 |
Why?
| | Tomography, X-Ray Computed | 4 | 2022 | 2272 | 0.310 |
Why?
| | Blood Glucose | 2 | 2016 | 1827 | 0.300 |
Why?
| | Needs Assessment | 2 | 2020 | 315 | 0.290 |
Why?
| | Chlorides | 7 | 2023 | 127 | 0.290 |
Why?
| | Clinical Trials as Topic | 2 | 2022 | 926 | 0.270 |
Why?
| | Polymorphism, Genetic | 1 | 2009 | 610 | 0.250 |
Why?
| | Alleles | 6 | 2023 | 789 | 0.230 |
Why?
| | Minimal Clinically Important Difference | 1 | 2023 | 10 | 0.230 |
Why?
| | Pregnancy, Unplanned | 2 | 2023 | 33 | 0.220 |
Why?
| | Patient Selection | 2 | 2019 | 629 | 0.220 |
Why?
| | C-Reactive Protein | 2 | 2018 | 362 | 0.220 |
Why?
| | Orphan Drug Production | 1 | 2023 | 6 | 0.220 |
Why?
| | Infertility, Male | 1 | 2023 | 59 | 0.220 |
Why?
| | Abortion, Spontaneous | 1 | 2023 | 89 | 0.210 |
Why?
| | Animals | 9 | 2022 | 31565 | 0.210 |
Why?
| | Ion Transport | 2 | 2021 | 54 | 0.210 |
Why?
| | Body Height | 1 | 2023 | 180 | 0.210 |
Why?
| | Fertility | 1 | 2023 | 128 | 0.200 |
Why?
| | Puberty | 1 | 2023 | 135 | 0.200 |
Why?
| | RNA, Messenger | 3 | 2022 | 2550 | 0.200 |
Why?
| | Azabicyclo Compounds | 1 | 2021 | 5 | 0.190 |
Why?
| | Epoxide Hydrolases | 1 | 2021 | 10 | 0.190 |
Why?
| | Observational Studies as Topic | 1 | 2022 | 90 | 0.190 |
Why?
| | Enzyme Activators | 1 | 2021 | 5 | 0.190 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 1836 | 0.190 |
Why?
| | Benzoates | 1 | 2021 | 38 | 0.190 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 249 | 0.190 |
Why?
| | Disease Progression | 5 | 2020 | 2371 | 0.180 |
Why?
| | Men's Health | 1 | 2020 | 7 | 0.180 |
Why?
| | Infertility | 1 | 2021 | 45 | 0.180 |
Why?
| | Women's Rights | 1 | 2020 | 3 | 0.170 |
Why?
| | Neutrophils | 3 | 2016 | 1089 | 0.170 |
Why?
| | Communicable Disease Control | 1 | 2020 | 67 | 0.170 |
Why?
| | Middle Aged | 12 | 2023 | 26605 | 0.170 |
Why?
| | Virulence Factors | 2 | 2014 | 139 | 0.170 |
Why?
| | Cataract | 1 | 2022 | 184 | 0.170 |
Why?
| | Asthma | 2 | 2023 | 2021 | 0.170 |
Why?
| | Aztreonam | 2 | 2016 | 8 | 0.170 |
Why?
| | Patient Reported Outcome Measures | 1 | 2022 | 251 | 0.170 |
Why?
| | Colistin | 1 | 2019 | 8 | 0.170 |
Why?
| | Sexism | 1 | 2020 | 43 | 0.170 |
Why?
| | Contraception Behavior | 1 | 2020 | 80 | 0.160 |
Why?
| | Medication Therapy Management | 1 | 2020 | 67 | 0.160 |
Why?
| | Receptors, Interleukin-8B | 1 | 2018 | 22 | 0.160 |
Why?
| | Health Status | 1 | 2023 | 716 | 0.150 |
Why?
| | Contraception | 1 | 2020 | 117 | 0.150 |
Why?
| | Pyrimidines | 1 | 2021 | 374 | 0.150 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2537 | 0.150 |
Why?
| | Administration, Oral | 1 | 2020 | 725 | 0.150 |
Why?
| | HEK293 Cells | 1 | 2020 | 590 | 0.140 |
Why?
| | Risk Assessment | 3 | 2021 | 2958 | 0.140 |
Why?
| | Leukocytes | 1 | 2018 | 272 | 0.140 |
Why?
| | Respiratory Tract Infections | 1 | 2021 | 319 | 0.140 |
Why?
| | Cytochrome P-450 CYP3A Inducers | 1 | 2017 | 5 | 0.140 |
Why?
| | Machine Learning | 1 | 2020 | 315 | 0.140 |
Why?
| | Pregnancy, High-Risk | 1 | 2017 | 12 | 0.140 |
Why?
| | Follow-Up Studies | 2 | 2023 | 4392 | 0.140 |
Why?
| | Prognosis | 2 | 2022 | 3315 | 0.140 |
Why?
| | Biological Availability | 1 | 2017 | 119 | 0.140 |
Why?
| | Research | 1 | 2020 | 389 | 0.140 |
Why?
| | Biphenyl Compounds | 1 | 2017 | 50 | 0.140 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 192 | 0.140 |
Why?
| | Attitude of Health Personnel | 1 | 2023 | 970 | 0.140 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1518 | 0.130 |
Why?
| | Risk Adjustment | 1 | 2017 | 76 | 0.130 |
Why?
| | Infant, Newborn | 3 | 2023 | 5038 | 0.130 |
Why?
| | Recovery of Function | 1 | 2020 | 573 | 0.130 |
Why?
| | Pilot Projects | 2 | 2020 | 1360 | 0.130 |
Why?
| | Pharmacogenetics | 1 | 2017 | 149 | 0.130 |
Why?
| | Epithelial Cells | 2 | 2020 | 946 | 0.130 |
Why?
| | Albuterol | 1 | 2016 | 102 | 0.130 |
Why?
| | Interferons | 1 | 2016 | 151 | 0.130 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 493 | 0.120 |
Why?
| | Staphylococcal Infections | 1 | 2019 | 340 | 0.120 |
Why?
| | Diabetes Complications | 1 | 2016 | 208 | 0.120 |
Why?
| | Body Mass Index | 2 | 2023 | 1957 | 0.120 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2014 | 36 | 0.120 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 373 | 0.120 |
Why?
| | Metalloproteases | 1 | 2014 | 37 | 0.120 |
Why?
| | Genetic Predisposition to Disease | 2 | 2015 | 2090 | 0.120 |
Why?
| | Biomarkers | 4 | 2022 | 3397 | 0.120 |
Why?
| | Bronchodilator Agents | 1 | 2016 | 239 | 0.110 |
Why?
| | Quorum Sensing | 1 | 2014 | 71 | 0.110 |
Why?
| | Health Services Accessibility | 1 | 2019 | 756 | 0.110 |
Why?
| | Administration, Inhalation | 3 | 2022 | 637 | 0.100 |
Why?
| | Wound Infection | 1 | 2013 | 30 | 0.100 |
Why?
| | Neutrophil Activation | 1 | 2013 | 78 | 0.100 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 61 | 0.100 |
Why?
| | Retrospective Studies | 8 | 2023 | 12521 | 0.100 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2016 | 505 | 0.100 |
Why?
| | Comorbidity | 1 | 2016 | 1447 | 0.100 |
Why?
| | Cellular Structures | 1 | 2011 | 3 | 0.100 |
Why?
| | Risk Factors | 3 | 2020 | 8614 | 0.100 |
Why?
| | United States | 4 | 2023 | 12137 | 0.090 |
Why?
| | Mycobacterium | 1 | 2013 | 103 | 0.090 |
Why?
| | Drug Therapy, Combination | 3 | 2021 | 949 | 0.090 |
Why?
| | Extracellular Space | 1 | 2011 | 116 | 0.090 |
Why?
| | Microbial Viability | 1 | 2011 | 79 | 0.090 |
Why?
| | Endoscopy | 2 | 2023 | 245 | 0.090 |
Why?
| | Patient Admission | 1 | 2012 | 175 | 0.090 |
Why?
| | Leukocytes, Mononuclear | 1 | 2013 | 489 | 0.090 |
Why?
| | Survival Rate | 2 | 2018 | 1638 | 0.090 |
Why?
| | Mass Screening | 1 | 2016 | 979 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 1726 | 0.090 |
Why?
| | Burns | 1 | 2013 | 237 | 0.080 |
Why?
| | Inflammation | 2 | 2022 | 2464 | 0.080 |
Why?
| | Blood Group Antigens | 1 | 2009 | 14 | 0.080 |
Why?
| | Inpatients | 1 | 2012 | 378 | 0.080 |
Why?
| | Mucus | 1 | 2009 | 54 | 0.080 |
Why?
| | Sexual Behavior | 2 | 2022 | 434 | 0.070 |
Why?
| | ADP Ribose Transferases | 1 | 2007 | 9 | 0.070 |
Why?
| | Aged | 4 | 2023 | 18969 | 0.070 |
Why?
| | Exotoxins | 1 | 2007 | 14 | 0.070 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2009 | 127 | 0.070 |
Why?
| | Phenotype | 1 | 2015 | 2784 | 0.070 |
Why?
| | Furin | 1 | 2007 | 12 | 0.070 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2007 | 17 | 0.070 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2322 | 0.070 |
Why?
| | Cyclic GMP | 1 | 2007 | 78 | 0.070 |
Why?
| | Registries | 3 | 2023 | 1764 | 0.070 |
Why?
| | Bacterial Toxins | 1 | 2007 | 103 | 0.070 |
Why?
| | Survivors | 1 | 2010 | 412 | 0.070 |
Why?
| | Sulfones | 1 | 2007 | 97 | 0.070 |
Why?
| | Respiratory System | 1 | 2007 | 137 | 0.060 |
Why?
| | Respiratory Mucosa | 1 | 2007 | 251 | 0.060 |
Why?
| | Respiration, Artificial | 1 | 2009 | 528 | 0.060 |
Why?
| | Piperazines | 1 | 2007 | 310 | 0.060 |
Why?
| | Logistic Models | 2 | 2019 | 1829 | 0.060 |
Why?
| | Reproductive Health Services | 1 | 2023 | 10 | 0.060 |
Why?
| | Nose | 1 | 2023 | 55 | 0.050 |
Why?
| | Cell Separation | 2 | 2016 | 290 | 0.050 |
Why?
| | Deoxyribonuclease I | 1 | 2022 | 34 | 0.050 |
Why?
| | Rare Diseases | 1 | 2023 | 88 | 0.050 |
Why?
| | Saline Solution, Hypertonic | 1 | 2022 | 39 | 0.050 |
Why?
| | Sex Education | 1 | 2022 | 30 | 0.050 |
Why?
| | Hot Flashes | 1 | 2023 | 72 | 0.050 |
Why?
| | Microbial Sensitivity Tests | 2 | 2014 | 300 | 0.050 |
Why?
| | Contraceptive Agents | 1 | 2022 | 54 | 0.050 |
Why?
| | Biofilms | 2 | 2014 | 223 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2009 | 1880 | 0.050 |
Why?
| | Nutritional Status | 1 | 2023 | 286 | 0.050 |
Why?
| | Preconception Care | 1 | 2021 | 30 | 0.050 |
Why?
| | Genetic Counseling | 1 | 2021 | 65 | 0.050 |
Why?
| | Attitude | 1 | 2022 | 228 | 0.040 |
Why?
| | Longevity | 1 | 2021 | 136 | 0.040 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2020 | 23 | 0.040 |
Why?
| | Menopause | 1 | 2023 | 271 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 479 | 0.040 |
Why?
| | Child, Preschool | 2 | 2023 | 9114 | 0.040 |
Why?
| | Sequence Analysis, DNA | 1 | 2022 | 722 | 0.040 |
Why?
| | Condoms | 1 | 2020 | 112 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2012 | 2087 | 0.040 |
Why?
| | Tetraspanin 30 | 1 | 2018 | 9 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2019 | 122 | 0.040 |
Why?
| | Genetic Testing | 1 | 2021 | 381 | 0.040 |
Why?
| | Ecosystem | 1 | 2023 | 500 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2016 | 3003 | 0.040 |
Why?
| | British Columbia | 1 | 2018 | 10 | 0.040 |
Why?
| | trans-Golgi Network | 2 | 2007 | 11 | 0.040 |
Why?
| | Morbidity | 1 | 2018 | 277 | 0.040 |
Why?
| | Gene Deletion | 1 | 2018 | 356 | 0.030 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2007 | 157 | 0.030 |
Why?
| | Drug Administration Routes | 1 | 2016 | 38 | 0.030 |
Why?
| | Leadership | 1 | 2020 | 291 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2018 | 3861 | 0.030 |
Why?
| | Genetic Variation | 1 | 2021 | 868 | 0.030 |
Why?
| | Depression | 1 | 2024 | 1133 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2023 | 1168 | 0.030 |
Why?
| | Practice Patterns, Physicians' | 1 | 2023 | 1175 | 0.030 |
Why?
| | Interferon-alpha | 1 | 2016 | 185 | 0.030 |
Why?
| | Colorado | 2 | 2018 | 4090 | 0.030 |
Why?
| | Rats | 1 | 2022 | 4913 | 0.030 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2014 | 61 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 813 | 0.030 |
Why?
| | Medication Adherence | 1 | 2018 | 531 | 0.030 |
Why?
| | Cohort Studies | 1 | 2023 | 4883 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 951 | 0.030 |
Why?
| | Survival Analysis | 1 | 2016 | 1206 | 0.030 |
Why?
| | Ciprofloxacin | 1 | 2013 | 23 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1422 | 0.030 |
Why?
| | Drug Synergism | 1 | 2013 | 315 | 0.020 |
Why?
| | Superoxides | 1 | 2013 | 190 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 314 | 0.020 |
Why?
| | Cell Line | 2 | 2007 | 2629 | 0.020 |
Why?
| | Suspensions | 1 | 2011 | 30 | 0.020 |
Why?
| | Enteral Nutrition | 1 | 2012 | 157 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 6306 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2011 | 426 | 0.020 |
Why?
| | Insulin Infusion Systems | 1 | 2012 | 298 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 341 | 0.020 |
Why?
| | Sex Distribution | 1 | 2010 | 336 | 0.020 |
Why?
| | Age of Onset | 1 | 2010 | 444 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1791 | 0.020 |
Why?
| | Time Factors | 1 | 2018 | 6077 | 0.020 |
Why?
| | Feedback, Physiological | 1 | 2007 | 68 | 0.020 |
Why?
| | Epithelial Sodium Channels | 1 | 2007 | 12 | 0.020 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2007 | 22 | 0.020 |
Why?
| | Guanylate Cyclase | 1 | 2007 | 32 | 0.020 |
Why?
| | Sodium | 1 | 2007 | 184 | 0.020 |
Why?
| | Purines | 1 | 2007 | 158 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 507 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2007 | 1003 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2007 | 445 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2012 | 1011 | 0.010 |
Why?
| | Patient Acceptance of Health Care | 1 | 2010 | 675 | 0.010 |
Why?
| | Mice | 2 | 2013 | 14843 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2013 | 3498 | 0.010 |
Why?
| | Insulin | 1 | 2012 | 2080 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2007 | 1947 | 0.010 |
Why?
| | Nitric Oxide | 1 | 2007 | 817 | 0.010 |
Why?
| | Macrophages | 1 | 2007 | 1259 | 0.010 |
Why?
| | Signal Transduction | 1 | 2007 | 4501 | 0.010 |
Why?
|
|
Taylor-Cousar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|